The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Abstract
Objective: To evaluate the efficacy and safety of rituximab in a randomized, double‐blind, placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. Methods: Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52. Results: Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab ( P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo‐treated patients and no rituximab‐treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti–double‐stranded DNA (anti‐dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti‐dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group. Conclusion: Although rituximab therapy led to more responders and greater reductions in anti‐dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationDevelopment of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citationMerrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Self-citationMycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Self-citationMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citationHoussiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Liang, M. H., Socher, S. A., Larson, M. G., & Schur, P. H. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320909 · Cited by 789
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Self-citationMaloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity
Lipsky, P. E. (2001) · Nature Immunology · doi:10.1038/ni0901-764 · Cited by 695
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
(2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440513 · Cited by 539
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27541 · Cited by 411
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Smith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Chang, A., Henderson, S. G., Brandt, D., Liu, N., Guttikonda, R., Hsieh, C., Kaverina, N., Utset, T. O., Meehan, S. M., Quigg, R. J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001983 · Cited by 360
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Isenberg, D., Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Jayne, D., Sánchez-Guerrero, J., Wofsy, D., Yu, X., & Solomons, N. (2010) · Rheumatology · doi:10.1093/rheumatology/kep346 · Cited by 356
Self-citationRituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
Ramos-Casals, M., Soto, M., Cuadrado, M., & Khamashta, M. (2009) · Lupus · doi:10.1177/0961203309106174 · Cited by 304
Vigna-Perez, M., Hernández-Castro, B., Paredes-Saharopulos, O., Portales-Pérez, D., Baranda, L., Abud-Mendoza, C., & González-Amaro, R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1954 · Cited by 303
Gunnarsson, I., Sundelin, B., Jónsdóttir, T., Jacobson, S. H., Henriksson, E. W., & van Vollenhoven, R. F. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22505 · Cited by 241
Grootscholten, C., Erythematosus, F. T. D. W. P. O. S. L., Ligtenberg, G., Hagen, E. C., van den Wall Bake, A. W. L., de Glas-Vos, J. W., Bijl, M., Assmann, K. J., Bruijn, J. A., Weening, J. J., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001630 · Cited by 237
Linnik, M. D., Hu, J. Z., Heilbrunn, K. R., Strand, V., Hurley, F. L., Joh, T., & LJP 394 Investigator Consortium (2005) · Arthritis & Rheumatism · doi:10.1002/art.20980 · Cited by 209
Radhakrishnan, J., Moutzouris, D.-A., Ginzler, E. M., Solomons, N., Siempos, I. I., & Appel, G. B. (2010) · Kidney International · doi:10.1038/ki.2009.412 · Cited by 207
Self-citationUpdates on the Treatment of Lupus Nephritis
Bomback, A. S., & Appel, G. B. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050472 · Cited by 177
Self-citationThe role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Ng, K. P., Cambridge, G., Leandro, M. J., Edwards, J. C. W., Ehrenstein, M., & Isenberg, D. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067124 · Cited by 160
Pepper, R. J., Griffith, M. E., Kirwan, C., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp336 · Cited by 157
Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis
Steinmetz, O. M., Velden, J., Kneissler, U., Marx, M., Klein, A., Helmchen, U. M., Stahl, R. A. K., & Panzer, U. (2008) · Kidney International · doi:10.1038/ki.2008.191 · Cited by 144
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
Tanaka, Y., Yamamoto, K., Takeuchi, T., Nishimoto, N., Miyasaka, N., Sumida, T., Shima, Y., Takada, K., Matsumoto, I., Saito, K., et al. (2007) · Modern Rheumatology · doi:10.1007/s10165-007-0565-z · Cited by 126
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
Eisenberg, R. A., & Albert, D. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0042 · Cited by 101
B cell depletion therapy in systemic lupus erythematosus
Anolik, J. H., Sanz, I., & Looney, R. J. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0020-x · Cited by 72
Self-citationB lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies
Bhat, P., & Radhakrishnan, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002663 · Cited by 61
Oral Cyclophosphamide for Lupus Glomerulonephritis
McKinley, A. M., Park, E., Spetie, D. N., Hackshaw, K. V., Nagaraja, S., Hebert, L. A., & Rovin, B. H. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02670409 · Cited by 54
Self-citationRituximab Therapy in Lupus Nephritis: Current Clinical Evidence
Ramos‐Casals, M., Díaz‐Lagares, C., Cárdenas, M. J. S., Brito‐Zerón, P., Cuadrado, M. J., Sanna, G., Bertolaccini, M. L., & Khamashta, M. A. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8205-3 · Cited by 46
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citation2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Metadata
- Authors
- Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., Appel, G., & LUNAR Investigator Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-03-27
- Volume
- 64
- Issue
- 4
- Pages
- 1215-1226
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1989273660
- Cited by
- 1,461
- References
- 44
- FWCI
- 79.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.